Select: The next prostate cancer prevention trial

E. A. Klein, I. M. Thompson, S. M. Lippman, P. J. Goodman, D. Albanes, P. R. Taylor, C. Coltman

Research output: Contribution to journalArticle

214 Scopus citations

Abstract

Purpose: Growing evidence implies that selenium and vitamin E may decrease the risk of prostate cancer. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a randomized prospective double-blind study designed to determine whether selenium and vitamin E decrease the risk of prostate cancer in healthy men. Materials and Methods: The preclinical and epidemiological evidence regarding chemoprevention with selenium and vitamin E were reviewed. Secondary analyses from randomized trials of the 2 agents were included in the current analysis. Data from these analyses as well as evidence from the Prostate Cancer Prevention Trial were used to develop the SELECT schema. Results: Preclinical, epidemiological and phase III data imply that selenium and vitamin E have potential efficacy for prostate cancer prevention. The experience of the Prostate Cancer Prevention Trial shows the interest and dedication of healthy men to long-term studies of cancer prevention. A total of 32,400 men are planned to be randomized in SELECT. Conclusions: SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment in the study is planned to begin in 2001 with final results anticipated in 2013.

Original languageEnglish (US)
Pages (from-to)1311-1315
Number of pages5
JournalJournal of Urology
Volume166
Issue number4
DOIs
StatePublished - Jan 1 2001

    Fingerprint

Keywords

  • Chemoprevention
  • Prostate
  • Prostatic neoplasms
  • Selenium
  • Vitamin E

ASJC Scopus subject areas

  • Urology

Cite this

Klein, E. A., Thompson, I. M., Lippman, S. M., Goodman, P. J., Albanes, D., Taylor, P. R., & Coltman, C. (2001). Select: The next prostate cancer prevention trial. Journal of Urology, 166(4), 1311-1315. https://doi.org/10.1016/S0022-5347(05)65759-X